Chapter 14: Chronic Myeloid Leukaemia

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

We take the densest source material, you know, the core texts that really define modern clinical practice, and we try to extract the essential game -changing knowledge you need.

Right, the stuff that really matters.

Exactly.

And today,

we are deep diving into a foundational topic in hematology, one that really serves as the gold standard for targeted cancer therapy, chronic myeloid leukemia, or CML.

This specific deep dive is absolutely crucial because CML is more than just another leukemia.

It represents a paradigm shift.

A paradigm shift

Well,

historically, a diagnosis of CML meant a life expectancy measured in just a few years.

Today, because of the discoveries we're about to explore, it's often managed as a chronic long -term condition.

It's the textbook example of molecular medicine succeeding.

Okay, so our mission today is to follow that clinical narrative, the one laid out in our source material.

We want to fully grasped the unique genetics that drive CML, walk through the complex spectrum of clinical and lab findings, and then the big one.

We need to dedicate significant time to unpacking the tyrosine kinase inhibitor revolution,

the TKIs, those drugs that changed absolutely everything, and how clinicians monitor the response to make sure it works long term.

Sounds like a plan.

So let's start by situating CML.

Where does it fit in the big picture of blood disorders?

Okay, so the current classification, this is based on the WHO 2016 system.

It places CML, specifically CML, that's BCR -ABL1 positive,

into a group called the mild proliferative neoplasms, or MPNs.

MPNs?

Right.

And this is basically a cluster of clonal disorders, and they all arise from a single pluripotent hematopoietic stem cell.

I want to stop on that definition.

Clonal disorder arising from a pluripotent stem cell.

What does that tell us right away?

What's the scope of the disease?

It tells us the genetic mistake happens right at the very top,

in the mother cell of the entire blood system.

And because that original stem cell is cluripotent, meaning it can become any myeloid cell, even lymphoid cells,

the genetic flaw gets passed down to almost every mature cell type in the blood.

So it explains the chaos you see later on.

Exactly.

It explains the chaos, but it also confirms just how deep the problem goes.

It's not a problem with one cell type, it's a problem with the whole factory.

And CML isn't a rare disease, is it?

No, it's a significant player.

It accounts for about 15 % of all leukemias.

And we have to remember the name chronic.

Right.

Chronic leukemias, unlike the acute ones, progress slowly.

We're talking over many years.

Acute leukemias are, well, they're explosive.

They progress over days or weeks.

CML, at least in its early phase, often lets patients live relatively symptom -free for a while.

Which is why, as the text says, half of all diagnoses are incidental, just found on a routine blood test.

Precisely.

That distinction between acute and chronic is fundamental.

Okay, so to understand why CML behaves this way, we have to get into the genetics.

Let's move to section one, the molecular driver.

Because CML is, really, it's defined almost entirely by one single molecular event.

It is.

We're talking about the Philadelphia chromosome,

or Fiesch -Curry chromosome.

This is one of the most famous genetic discoveries in all of human medicine.

And it's in almost every case.

Nearly every single one.

We're talking 98 % of CML cases are defined by the presence of this acquired abnormality.

Okay, so let's get specific.

What is the structural flaw?

What is actually happening to chromosomes 9 and 22?

It's a classic reciprocal translocation.

Its designation is T922Q34Q11.

So if you imagine chromosomes 9 and 22 sitting next to each other,

the translocation means they literally swap pieces of genetic material.

A section of the long arm of chromosome 9 breaks off and gets changed with a section from the long arm of chromosome 22.

And what are the key genes that get caught up in this swap?

Well, the ABL1 oncogene, which is normally on chromosome 9, gets moved.

It's physically moved and fused onto the BCR gene, which lives on chromosome 22.

And the result of that swap?

The result is a shortened, structurally abnormal chromosome 22.

And that is what we call the Philadelphia chromosome.

So the Fiesch chromosome is the product of this fusion, and it's actually the broken chromosome 22.

This creates a whole new genetic blueprint.

A whole new blueprint.

Exactly.

The genetic code that results from this translocation is called the BCR -ABL1 chimeric gene.

And the protein that this new gene makes, well, that's the true molecular driver of the disease.

This is where the story gets really compelling.

All right.

So tell us about this villain protein.

What does this new blueprint produce?

So this fusion gene typically codes for something called a P210 fusion protein.

Now, the normal ABL1 gene makes a protein that's 145 kilodea, and it has this

tightly regulated tyrosine kinase activity.

Like an on -off switch.

A perfect analogy.

It's an on -off switch for cell signals, but it's kept off most of the time.

The P210 protein, however, is profoundly different.

It has what we call constitutively active tyrosine kinase activity.

Constitutively active.

So permanently switched on.

Permanently on.

The switch is broken.

Stuck in the on position.

What does that do to the cell?

It means the enzyme is just firing constantly.

Way in excess of the normal ABL1 protein.

Think of it like with the accelerator jammed to the floor and the brakes cut.

This enzyme sends nonstop signals for the cell to divide, to ignore signals for programmed cell death, and just to proliferate uncontrollably.

And that's the engine.

That constant unchecked signaling is what drives the massive overproduction of white blood cells.

That's the hallmark of CML.

It's a perfect one -to -one relationship.

The translocation is the injury,

the BCR -ABL1 gene is the defect, and the always -on tyrosine kinase is the mechanism.

It's why CML is so unique, then.

It is.

It's a cancer that's addicted to a single, distinct molecular driver.

I should probably add, just for completeness, that you can see this same translocation in acute lymphoblastic leukemia, ALL.

Oh, really?

Yeah.

But the breakpoint in the BCR gene is different, so it makes a smaller protein, a P190 protein.

So even though the pH chromosome is there in both, the specific gene breakpoint determines which leukemia you get.

P210 is the standard for CML.

Okay.

So, given this chromosome is the definitive marker,

how do clinicians actually find it?

How do they confirm it's there?

Well, the historical and most direct method is a karyotypic examination.

You look at the chromosomes of the cancer cells under a microscope.

And you can just see it.

You can.

When the cells are dividing, in metaphase, a technician can physically see the shortened chromosome 22, the pheochromosome, and the newly elongated chromosome 9, the very visual confirmation of that physical swab.

But karyotyping has a limitation, doesn't it?

The cells have to be actively dividing.

It does.

And in a small number of cases, maybe we don't visually see the pheochromosome under the microscope.

We call these cases phe -negative.

But if the clinical picture screams CML,

we have to use more sensitive molecular techniques, because the rearrangement might still be there, just hidden.

And this is where things like fluorescence in situ hybridization, or FISH, come into play.

Exactly.

FISH is incredibly useful because it works on cells that aren't dividing.

We use these tiny colored fluorescent probes.

Imagine a red tag for the ABL gene and a green tag for the BCR gene.

In a normal cell, you'd see red and green signals, but they'd be separate.

When the translocation happens, the two genes get stuck together, and so the red and green probes fuse.

You get a yellow signal.

So you can screen thousands of cells very quickly and spot that yellow fusion signal.

And the most sensitive method of all, the one used for long -term monitoring.

That would be reverse transcriptase PCR, or RT -PCR.

This test detects the actual BCR -ABL1 transcript, the messenger RNA, in the patient's cells.

It's the gold standard for diagnosis and, crucially, for tracking the disease during therapy.

So to be clear, if a patient is phe -negative on a karyotype, but they are RT -PCR positive for BCR -ABL1.

You treat them exactly like standard CML.

The molecular driver is identical.

This is completely different from something called atypical CML, which is BCR -ABL1 negative and is a totally distinct, more aggressive syndrome.

That clarity is vital.

Now, let's go back to that pluripotent stem cell origin.

If the flaw is in the founding cell, what does that mean for how the disease progresses?

Right.

Since the ph chromosome is acquired in that earliest stem cell, we find the abnormality everywhere.

It's in the entire myeloid line, granulocytes, red cells, platelets, and in the lymphoid line, so B and T cells.

And that's a critical point.

It's critical because it dictates the pathway of disease progression.

The goal is always to keep the disease in its chronic, manageable phase,

but the main cause of death is transformation.

The disease evolving.

Absolutely.

The main threat is the evolution to an accelerated phase and then inevitably to the blast phase, which is full -blown acute leukemia.

And because that original clone had both myeloid and lymphoid potential, the blast phase can erupt as either myeloid -like or lymphoid -like acute leukemia.

Okay.

That sets the molecular stage perfectly.

Let's shift our attention now to section two, clinical presentation.

If the white cell factory is permanently switched on, what does the patient actually look like?

CML is most common in that there's a slight male predominance, about 1 .4 to 1.

But the most striking thing, as you said earlier, is that 50 % of people are diagnosed incidentally.

They just go for a checkup.

Right.

Routine blood count and the numbers just jump off the page.

For the other half though, what are the symptoms that push them to see a doctor?

The symptoms tend to fall into a few key groups and they're all driven by the sheer volume of cells being produced and broken down.

The first is what we call hypermetabolism.

The body's just running too hot.

That's a great way to put it.

It's running this massive energy -intensive factory of white cells.

This leads to profound fatigue, what we call lassitude, unexplained weight loss, anorexia, and drenching night sweats.

And what's the most common physical finding on exam?

Spleenomegaly.

The spleen is the main filter for blood cells.

And in CML, it's working overtime.

It's almost always present and often it is massive.

When you say massive, what are we talking about here?

We're not talking about just feeling the tip under the ribs.

In advanced chronic phase CML, the spleen can extend all the way down into the pelvis.

This huge organ causes a lot of discomfort, pain, and because it presses on the stomach, it causes early satiety and digestion.

Which just feeds back into the weight loss and anorexia.

It's a vicious cycle.

It's a very clear physical sign of just how big the disease burden is.

And despite this overabundance of white cells, patients often have signs of anemia.

Why is that?

That's the third group of symptoms.

Anemia is very common, usually normochromic and normocytic.

And it's because the bone marrow is so jam -packed with malignant white cells that it crowds out normal red cell and platelet production.

Plus, the huge spleen can contribute to destroying some red cells.

So you get pallor, shortness of breath.

Exactly.

Dysnoea and a compensating rapid heartbeat tachycardia.

What about bleeding and clotting?

With so many cells, you'd think clotting would be the problem.

It's a bit counterintuitive.

The fourth group of symptoms is often bleeding issues.

Patients might have easy bruising, nosebleeds, heavy periods.

And while the platelet count is often increased, thrombocytosis is common.

But the platelets are often functionally abnormal.

They don't work properly.

So you get poor hemostasis.

And the final set of symptoms, that goes right back to that massive cell turnover you mentioned.

Exactly.

Hyperuricamia.

When you have cells dividing and dying that rapidly, you break down huge amounts of nucleic acids, specifically perines.

This leads to an overproduction of uric acid.

Which can cause gout.

It can cause very painful gout, or if it's severe and chronic, even renal impairment.

It's a key biochemical sign of that proliferative activity.

And then you get the rare, really dramatic symptoms

hyperviscosity, the blood literally getting two thick things like priapism or visual disturbances.

That is a very comprehensive picture.

So now let's connect that to the essential lab findings that would confirm the suspicion.

The number one feature is a dramatic leukocytosis.

The white cell count can easily be over 200 times 10 to the nine per liter.

If you were just spin down a blood sample from a CML patient, you'd see it visually.

The buffy coat, that white cell layer, would be massive.

So let's talk about the peripheral blood film.

If you look under the microscope, what makes CML look different from, say, acute myeloid leukemia?

This is the definitive diagnostic clue for the chronic phase.

In AML, the blood is just full of immature blast cells.

But in chronic phase CML, you see a complete spectrum of myeloid cells.

The whole family tree is there.

The whole family tree, all circulating together.

You'll see blast cells, promyelocytes, myelocytes, metamyelocytes, bands, and segmented neutrophils.

It's like a snapshot of the entire production line.

A traffic jam of cells at every stage of development.

Precisely.

But here is the key diagnostic point.

In the chronic phase,

the number of the more mature cells, the neutrophils and myelocytes, exceeds the number of the most immature cells, the blasts and promyelocytes.

That ratio is key.

If the blasts start to dominate, you're heading into the accelerated or acute phase.

And are there any specific cell types that really stand out?

Yes.

An increased number of circulating basal fields is a very characteristic and highly suspicious feature of CML.

And in the bone marrow itself, it's what you'd expect.

Intensely hypercellular.

Just packed with granulocytes.

Okay.

So we've got the clinical picture, the huge white count, the specific cell spectrum, the big spleen.

You tie it all together with the genetic confirmation.

Absolutely.

The presence of that BCR ABL1 gene on RT -PCR and the ph chromosome on cytogenetics confirms the diagnosis in 98 % of cases.

And we also screen for other genetic clues that tell us about prognosis right from the start.

You mean things like ASXL1, IKZF1 and RUNX1?

Correct.

We look for these co -occurring mutations because patients who have them on top of the BCR ABL1 fusion tend to have a less favorable prognosis.

Their disease is showing more genetic instability from day one, which makes them more likely to transform to acute leukemia.

This brings us perfectly to section three, which is really the turning point of the whole CML story.

Historically, prognosis was poor and you had scoring systems like SOQL to try and predict outcomes.

Yeah, the SOQL and Hasford scores were based on things like age, blast counts, spleen size.

They were essential when all we had was chemo or very high -risk transplants.

They were a measure of the disease's natural history.

But now.

Now, they're largely historical footnotes.

The single most important, most useful measure of prognosis today is simply how quickly and how deeply the patient responds to targeted therapy.

Let's talk about that targeted therapy.

The tyrosine kinase inhibitors or TKIs and the place to start has to be imatinib.

Imatinib or Gleevec completely transformed this disease.

It's the primary treatment for chronic phase CML.

And to understand its impact, you have to look at its specific mode of action.

Okay, so let's use that enzyme analogy again.

The BCR ABL1 protein is the always on kinase, but it needs fuel to work, which it gets from ATP.

Exactly.

Imatinib is a small molecule designed to be a competitive antagonist.

Think of it as a custom -made plug that fits perfectly into the power socket of the BCR ABL1 enzyme.

It docks right into the ATP binding site.

So it blocks the fuel source.

It physically prevents ATP from binding.

So no fuel, no energy transfer.

The phosphorylation stops, the constitutively active enzyme is shut down, the nonstop growth signal stop, and the malignant cell is basically starved or pushed into apoptosis.

And it's targeted.

That's the beauty of it.

It specifically targets the BCR ABL1 protein, which is only in the cancer cells.

So it bypasses most of the toxicity of general chemotherapy.

It's like surgical medicine at a molecular level.

What was the clinical impact of this first drug, imatinib?

It's still the drug we have the most experience with, and it's now the cheapest.

About 60 % of patients get an excellent long -term response and can stay on imatinib indefinitely, which is a massive win.

But about 40 % of patients will eventually need to switch.

Why do they switch?

Is it the drug failing or side effects?

It's a mix of both.

About half the time, it's an inadequate response.

The disease is starting to push back.

The other half involves intolerance to the side effects.

While it's much better than chemo, imatinib can cause rash, nausea, mild suppression,

and critically fluid retention periorbital edema is common, and muscle cramps.

If those are bad enough, you have to Which moves us to the second -generation drugs developed to overcome those issues.

Let's talk about nilatinib and dustatinib.

These are the second -gen TKIs.

They were designed to be more potent and have different binding profiles.

Some centers will even use them first -line because they can achieve a more rapid and deeper molecular response than imatinib.

They're also the standard second -line choice after imatinib fails.

Is there anything unique about dustatinib's mechanism?

Dustatinib is a dual inhibitor.

It hits not only BCR -ABL1, but also the SRC family kinases, so it has greater target inhibition.

Clinically, you have to watch for specific side effects, like pulmonary hypertension and, quite commonly, pleural effusions fluid around the lungs.

Nilatinib is more potent against BCR -ABL1 specifically.

Its side effects also include mild suppression.

But clinicians have to pay close attention to the risk of a prolonged QT interval on the ECG, which can lead to cardiac arrhythmias.

It's also linked to peripheral arterial disease.

Okay, now we're getting into the really specialized territory, the third -generation TKIs designed for tough resistance.

Let's start with basutanib.

Basutanib fits into that second -generation profile, also hitting both BCR -ABL1 and SRC kinases.

It's often used when there's resistance or intolerance to the earlier drugs.

Its main side effects tend to be gastrointestinal diarrhea is common, and you have to monitor liver function.

But the ultimate resistance fighter is ponatin.

It was designed to beat the single most problematic mutation in CML, T315I.

Why is that mutation so bad?

This is a really critical point about protein structure.

T315I is a point mutation where one amino acid threonine gets replaced by another, isoleucine.

Threonine is small, isoleucine is bigger and bulkier.

This substitution creates what we call steric hindrance in the binding pocket.

Steric hindrance, so a physical blockage.

A physical blockage, exactly.

The first and second -generation drugs like imatinib literally cannot fit into the binding site anymore.

The T315I mutation walls off the drug target, making most of the other TKIs useless.

Before podatinib, patients with this mutation had very few options.

So how does ponatinib get around this?

It's a multi -targeted TKI with unique chemical structure.

It doesn't rely on the same binding geometry.

It's shaped in a way that allows it to bind to the enzyme, even with that bulky isoleucine in the way.

It's the only drug we have that's effective against this mutation.

That makes it a lifeline, but it comes at a major cost, right?

It does.

It's all the molecular problem, but it comes with the highest risk of serious arterial and venous thrombosis blood clots.

We're talking heart attacks and strokes.

So clinicians have to a very careful risk -benefit calculation.

It's reserved for when T315I is confirmed or other highly resistant situations.

It is not a drug to be used lightly.

And finally, we have eskiminib, which has a completely novel mechanism.

Eskiminib is really exciting because it avoids that main binding site altogether.

All the others bind where ATP is supposed to go.

Eskiminib binds to a completely different spot called the myriastoil pocket.

And what's the advantage of targeting that spot?

It works through an allosteric mechanism.

By binding the myriastoil pocket, eskiminib forces the whole enzyme into an inactive shape.

And because it ignores the main ATP binding site, it can work in patients who have resistance mutations there.

It offers a totally different way to shut the enzyme down.

Wow.

That whole toolkit of drugs, each with its own profile, really underscores the need for precise objective monitoring.

This isn't just about the patient feeling better.

Monitoring is absolutely essential and very structured.

We have to see if we're hitting predetermined milestones.

It's typically done at 3, 6, and 12 months, using both karyotyping and, most importantly, RT -PCR to measure the BCR -ABL1 transcripts.

So let's define those milestones, starting with the cytogenetic response.

Cytogenetic response is the older method, based on looking for the pH chromosome.

The main goal here is a complete cytogenetic response, or CCER.

Which means?

It means we see a complete abscess of any phylloxel cells in the bone marrow.

The source material has a great illustration showing how, over about six months of good therapy, the percentage of those phyllo -positive cells should drop to zero.

That only tells you about the chromosome.

The molecular response with RT -PCR is much more sensitive.

Much more.

This is where we measure the ratio of malignant BCR -ABL1 transcripts to normal ABL1 transcripts, we express it as a percentage on a log scale.

We track the reduction in logs.

Okay, let's unpack that log scale, because it can be confusing.

Why is a log reduction so significant?

A log scale is exponential.

A one log reduction means the transcript level is 10 times lower.

It's down to 10 % of baseline.

A two log reduction is 100 times lower, down to 1%.

So we're wiping out the disease exponentially.

And the ultimate goal is to achieve a major molecular remission, or MMR.

And what does MMR mean on that log scale?

MMR is a three -log reduction.

That means the BCR -ABL1 transcript level is at 0 .1 % or better.

In real terms, for every 1 ,000 normal ABL1 transcripts, we only find one malignant one.

It's incredibly sensitive, and it's the standard for successful long -term control.

This precision lets clinicians use very structured criteria to define success and failure at specific time points.

These criteria are invaluable.

We classify response as optimal, warning, or failure.

And maybe the most critical early marker is the response at three months.

The early molecular response, or EMR.

And EMR is defined as the BCR -ABL1 transcript level being at or below 10 % at the three -month mark.

If you hit that, it's an optimal response.

You stay on your TKI.

If you fail to hit that, if you're still above 10%, that is the first major warning sign.

It means the disease is less sensitive and the long -term outlook is less favorable.

And how do those criteria evolve over the first year?

By six months.

We want to see the transcript level below 1%.

If you're still between 1 % and 10%, you're in the warning zone.

And by 12 months, we want to see that MMR status at or below 0 .1%.

If you haven't reached that by 12 months, it's classified as treatment failure, even if you feel perfectly fine.

So if a patient is in that warning zone, say it's six months, what's the next step?

You don't just switch them immediately, do you?

Not always, no.

The warning zone means you monitor them more closely.

You

have to change strategy.

That's defined by a few things.

Losing your complete hematological response so your blood counts get worse again, losing a CCRR, or a definitive loss of MMR.

If your transcript levels stay above 0 .1 % after a year or if they start rising significantly after you've hit MMR, that's failure.

And when failure happens, you go back to mutation screening?

Immediately.

You have to sequence the ADL1 gene.

You need to know exactly which mutation is causing the resistance, and that result guides your choice of the next TKI.

If you find the T315I mutation, you know you have to consider ponatinib.

This is truly individualized, molecularly guided cancer therapy.

This level of precision has just led to staggering long -term outcomes.

We have to reflect on that.

The change is phenomenal.

If you look at the survival curves now, after five years on a TKI, progression -free survival,

so staying in the chronic phase is between 85 and 90%.

Overall survival is over 90%.

This disease has been transformed from a death sentence into a manageable chronic illness.

And for some patients, the control is so deep that doctors are actually trying to stop the therapy altogether.

That's the concept of treatment -free remission, or TFR.

For patients who get a sustained deep molecular response, usually staying transcript negative for several years, about 60 % of them can successfully stop their TKI and stay in remission.

Potentially cured.

But it relies on constant molecular monitoring, because if the transcripts start to rise again, you restart the TKI, and you almost always regain control quickly.

Before we talk about the more aggressive stages, let's briefly touch on the other therapies, the ones that are now more historical or for special cases, like chemotherapy.

Historically, drugs like hydroxycarbamide or hydroxyurea were used to just knock down the number of BCR -ABL1 positive cells.

They didn't touch the root cause.

So they've been almost entirely replaced by TKIs.

And omacetaxine is mentioned as an option for relapse disease.

Right.

Omacetaxine is an inhibitor of protein translation.

It's a completely different mechanism, so it's a good option for relapse to refractory CML, especially when TKI resistance is a major problem.

And then there's alpha interferon.

It used to be a mainstay, but now it has one very

crucial role.

Interferon was used with chemo, but it wasn't that effective.

And the side effects were awful, really severe flu -like symptoms.

It's been completely replaced by TKIs.

The only critical use for it now is in managing pregnant patients.

Because TKIs are teratogenic.

Exactly.

They can cause birth defects and so can hydroxycarbamide.

So interferon is a way to suppress the disease during pregnancy until TKI therapy can be safely resumed after delivery.

Now let's move to the one truly curative option, but also the most high risk.

Allogeneic Stem Cell Transplant, or SCT.

SCT is the only treatment that offers a potential for an outright cure by replacing the patient's entire malignant blood system with a healthy donor system.

But the risks are significant, so it's reserved for very specific scenarios.

Like TKI failure?

Yes.

TKI failure that you can't manage by switching to another TKI.

Or for patients who present directly in the more accelerated or acute phases.

Timing is critical, though.

The outcomes are much better.

Five -year survival is 50 to 70 % if the transplant is done while the patient is still in the more stable chronic phase.

And what if a patient relapses after a transplant?

This is a really remarkable feature.

If you catch the relapse early, usually by seeing those BCR -ABL1 transcripts start to rise, you can give them donor leukocyte infusions or DLI.

What does that do?

You're basically giving them an infusion of lymphocytes from their original donor to reestablish the immune system's graft versus leukemia effect.

And that alone can often clear the malignant cells without needing a whole second transplant.

The decision -making process for younger patients with a suboptimal response seems very logical in the management algorithm.

It is.

It's a clear flow.

A patient starts Imatinib.

Their response is suboptimal.

You don't wait.

You immediately screen for two things at once.

A suitable SCT donor and a TKI resistance mutation.

And those results guide the next step.

Exactly.

If there's no resistance mutation, you switch to a second -gen TKI, like dosinibib.

If a mutation is found, you pick the TKI that works against it, like ponitinib for

T3UV5I.

Only if these next lines of TKI therapy fail is SCT really considered.

It's moved from the first -line cure attempt to a salvage therapy for defined failures.

We've spent most of our time the well -controlled chronic phase, which is great news.

But we have to conclude by looking at the ultimate threat,

disease progression.

What defines that shift into the accelerated phase?

The accelerated phase is a warning period.

It's an intermediate stage that lasts for months, and it signals that the disease is becoming more genetically unstable and much harder to control.

What are the specific criteria for that?

There are several.

We look for increasing anemia, the platelet count dropping below 100, a big increase in blood basophils over 20 percent, or the blast count in the marrow or blood rising to between 10 and 19 percent.

So not acute yet, but getting there.

Precisely.

You also see the spleens start to get bigger again, even on therapy.

The marrow might become fibrotic.

And crucially, you might see new chromosomal abnormalities appear on top of the original phage chromosome, which confirms this increasing genetic chaos.

And this carols the transition to the final, lethal stage, blast transformation.

Blast transformation is the rapid progression to acute leukemia.

It happens over days or weeks,

and it's defined as having greater than 20 percent blasts in the blood or bone marrow.

At this point, the disease is indistinguishable from aggressive acute leukemia.

And because the disease started in that pluripotent stem cell, the acute leukemia can take two forms.

Yes.

In about a fifth of cases, the transformation is lymphoblastic, so it looks like AL.

These patients can sometimes respond for a little while to ALL type chemotherapy.

But most go down the myeloid path.

The majority progress to an AML -like disease.

And these are exceptionally difficult to treat.

Survival is rare beyond a year without a successful allogeneic SCT because the standard chemo we use for new AML just doesn't work well against this highly resistant AFE -positive clone.

Do the TKIs still work in this acute setting?

They're still valuable, but their effect is very short -lived.

Resistance usually develops within weeks.

So allogeneic SCT remains the most valuable and often the only truly life -saving option if the patient is eligible.

This whole deep dive has really been a testament to the power of understanding molecular biology.

We started with one microscopic flaw, and now there's this entire successful multi -drug therapeutic landscape built on that knowledge.

It really is the pinnacle of personalized medicine.

CML provides the blueprint for how we should approach all cancers.

Find the driver,

then invent the specific inhibitor.

Let's consolidate our final crucial takeaways from this deep dive into chronic myeloid leukemia.

Okay, so first, CML is fundamentally defined by the Philadelphia chromosome, the T922 translocation, which creates the BCR -ABL1 fusion gene.

Right, and that fusion protein is a constitutively active tyrosine kinase, the engine that's always telling the cell to divide.

And this single molecular addiction made CML the prototype for targeted therapy.

The TKIs, led by Imatinib, lock that engine, shutting down the oncogenic signal, and completely changing the prognosis.

The diagnosis relies on finding that massive leukocytosis, often with a massive spleen, and confirming the BCR -ABL1 gene is present while seeing that characteristic complete spectrum of myeloid cells on the blood film.

And monitoring success relies on highly sensitive RT -PCR.

You track the transcript levels on a log scale, and the goal is a major molecular remission, or MMR, which is a three log reduction, or less than or equal to 0 .1 % transcript level.

And that early molecular response at three months is the crucial first checkpoint.

Absolutely.

The success has just been overwhelming.

Progression -free survival is over 85%, and SET is now reserved for specific failures.

But you have to weigh the risks of newer agents like Panatinib carefully against the life -saving potential they offer.

So, reflecting on this, the discovery and successful targeting of a single driver, BCR -ABL1, turned a lethal leukemia into a manageable chronic condition.

It just sets the bar for all of oncology.

It makes you ask, how many other complex aggressive diseases could we bring to heal if we could just find their single molecular Achilles heel?

That is the enduring legacy of CML, a powerful thought to end on.

Thank you for joining us as we guide you through this incredibly complex and rewarding material.

We appreciate you trusting us with your knowledge acquisition.